“Ozempic is bad for your heart.”
What the evidence shows
The strongest evidence points the opposite way. In SELECT (17,604 adults with overweight/obesity and established heart disease but no diabetes, NEJM 2023), semaglutide 2.4 mg reduced the combined risk of cardiovascular death, heart attack, or stroke by about 20% (hazard ratio 0.80) over roughly three years — a result that earned Wegovy an FDA indication to reduce cardiovascular events. The one real cardiac wrinkle is minor and labeled: GLP-1 drugs modestly raise resting heart rate (typically a few beats per minute), the clinical importance of which appears small against the demonstrated reduction in hard cardiovascular events.
What we still don’t know
The proven cardiovascular benefit is established for the specific studied groups — people with existing heart disease plus obesity or diabetes. Whether an otherwise healthy person taking the drug cosmetically gets the same protection is an extrapolation the trials didn't test. The long-term meaning of the small heart-rate increase, and effects in people with certain arrhythmias, are less fully characterized.
Why the claim misleads
"Bad for your heart" contradicts top-tier trial evidence in the populations most likely to worry about their hearts. It likely conflates the modest heart-rate bump — a real but minor effect — with harm, while ignoring that the drug measurably lowered heart attacks and strokes. Overstating a small physiologic change into "bad for your heart" is exactly the kind of headline that buries a genuinely favorable cardiovascular result.
Graded by The Peptide Era · evidence, not hype